

Avelumab

Catalog No: tcsc0030892



Available Sizes

Size: 1mg

Size: 5mg

Size: 20mg



Specifications

CAS No:

1537032-82-8

Formula:

N/A

Pathway:

Immunology/Inflammation

Target:

PD-1/PD-L1

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Alternative Names:

Anti-Human PD-L1, Human Antibody;MSB 0010718C; MSB0010718C

Observed Molecular Weight:

1000

Product Description

Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.

IC50 & Target: PD-1/PD-L1^[1]

In Vitro: Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity property. Avelumab increases NK-cell lysis 3.1-fold ($P=0.01$) in JHC7 cells relative to isotype control. When the cells are treated with IFN- γ , Avelumab markedly enhances NK-cell lysis relative to isotype control in the following cell lines: JHC7 (7.56-fold; $P=0.001$), UM-Chor1 (7.34-fold; $P[1]$). Results also demonstrate that the addition of Avelumab increases the frequency of antigen-specific multifunctional CD8⁺ T cells by more than fivefold, relative to the isotype control in CEFT-stimulated peripheral blood mononuclear cells (PBMCs)^[2].

In Vivo: Measurement of individual tumors clearly shows a slowing of tumor growth in the Avelumab-treated mice. By day 36 post-tumor implantation, there is a significant ($P[3]$).



Avelumab

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!